Free Trial

Eton Pharmaceuticals (ETON) Financials

Eton Pharmaceuticals logo
$20.04 +0.23 (+1.16%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$20.52 +0.48 (+2.42%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Eton Pharmaceuticals

Annual Income Statements for Eton Pharmaceuticals

This table shows Eton Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-3.82 -0.94 -9.02
Consolidated Net Income / (Loss)
-3.82 -0.94 -9.02
Net Income / (Loss) Continuing Operations
-3.82 -0.94 -9.02
Total Pre-Tax Income
-3.81 -0.69 -9.02
Total Operating Income
-2.60 -1.19 -8.26
Total Gross Profit
23 21 14
Total Revenue
39 32 21
Operating Revenue
39 32 21
Total Cost of Revenue
16 11 6.93
Operating Cost of Revenue
16 11 6.93
Total Operating Expenses
26 22 23
Selling, General & Admin Expense
23 19 19
Research & Development Expense
3.26 3.32 4.00
Total Other Income / (Expense), net
-1.21 0.50 -0.76
Other Income / (Expense), net
-1.21 0.50 -0.76
Income Tax Expense
0.02 0.25 0.00
Basic Earnings per Share
($0.15) ($0.04) ($0.36)
Weighted Average Basic Shares Outstanding
25.90M 25.65M 25.15M
Weighted Average Diluted Shares Outstanding
26.82M 25.69M 25.46M
Weighted Average Basic & Diluted Shares Outstanding
26.82M 25.69M 25.46M

Quarterly Income Statements for Eton Pharmaceuticals

This table shows Eton Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-0.60 0.63 -3.04 -0.81 -2.26 -0.58 4.56 -2.66 0.91 -3.05
Consolidated Net Income / (Loss)
-0.60 0.63 -3.04 -0.81 -2.26 -0.58 4.56 -2.66 0.91 -3.05
Net Income / (Loss) Continuing Operations
-0.60 0.63 -3.04 -0.81 -2.26 -0.58 4.56 -2.66 0.91 -3.05
Total Pre-Tax Income
-0.51 0.50 -2.99 -0.81 -2.01 -0.58 4.56 -2.66 0.91 -3.05
Total Operating Income
0.63 0.51 -2.94 -0.80 -1.99 -0.55 3.88 -2.53 1.06 -2.90
Total Gross Profit
6.48 6.30 5.63 5.01 3.63 4.40 9.68 3.35 6.36 2.02
Total Revenue
12 10 9.07 7.97 7.31 7.03 12 5.30 8.50 3.22
Operating Revenue
12 10 9.07 7.97 7.31 7.03 12 5.30 8.50 3.22
Total Cost of Revenue
5.17 4.02 3.45 2.96 3.68 2.63 2.32 1.96 2.14 1.20
Operating Cost of Revenue
5.17 4.02 3.45 2.96 3.68 2.63 2.32 1.96 2.14 1.20
Total Operating Expenses
5.85 5.79 8.56 5.81 5.62 4.95 5.80 5.88 5.30 4.91
Selling, General & Admin Expense
6.72 5.29 5.59 5.16 4.58 4.34 4.67 5.35 4.35 4.17
Research & Development Expense
-0.87 0.51 2.97 0.65 1.05 0.62 1.13 0.54 0.94 0.74
Total Other Income / (Expense), net
-1.14 -0.01 -0.05 -0.01 -0.02 -0.03 0.68 -0.13 -0.15 -0.15
Other Income / (Expense), net
-1.21 0.00 0.00 0.00 -0.30 0.00 0.80 0.00 -0.52 0.00
Income Tax Expense
0.09 -0.13 0.05 0.00 0.25 0.00 0.00 0.00 - 0.00
Basic Earnings per Share
($0.02) $0.02 ($0.12) ($0.03) ($0.10) ($0.02) $0.18 ($0.10) $209.82 ($0.12)
Weighted Average Basic Shares Outstanding
25.90M 25.90K 25.78M 25.76M 25.65M 25.72K 25.59M 25.53M 25.15M 25.37M
Weighted Average Diluted Shares Outstanding
26.82M 26.55K 25.78M 25.76M 25.69M 25.72K 25.98M 25.53M 25.46M 25.37M
Weighted Average Basic & Diluted Shares Outstanding
26.82M 25.84M 25.84M 25.69M 25.69M 25.66M 25.65M 25.50M 25.46M 25.30M

Annual Cash Flow Statements for Eton Pharmaceuticals

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-6.45 5.08 1.90
Net Cash From Operating Activities
0.97 6.82 4.82
Net Cash From Continuing Operating Activities
0.97 6.75 4.82
Net Income / (Loss) Continuing Operations
-3.82 -0.94 -9.02
Consolidated Net Income / (Loss)
-3.82 -0.94 -9.02
Depreciation Expense
1.15 0.90 1.77
Amortization Expense
1.11 0.12 0.13
Non-Cash Adjustments To Reconcile Net Income
6.47 5.96 5.05
Changes in Operating Assets and Liabilities, net
-3.94 0.71 6.89
Net Cash From Investing Activities
-40 -0.78 -2.79
Net Cash From Continuing Investing Activities
-40 -0.78 -2.79
Purchase of Property, Plant & Equipment
-0.03 0.00 -0.04
Acquisitions
-40 -0.78 -2.75
Net Cash From Financing Activities
33 -0.96 -0.13
Net Cash From Continuing Financing Activities
33 -0.96 -0.13
Repayment of Debt
-1.16 -1.16 -0.39
Issuance of Debt
25 0.00 0.00
Issuance of Common Equity
7.25 0.23 0.17
Other Financing Activities, net
1.19 -0.03 0.08
Cash Interest Paid
0.67 0.84 0.73
Cash Income Taxes Paid
0.08 0.25 0.00

Quarterly Cash Flow Statements for Eton Pharmaceuticals

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-5.33 2.57 1.04 -4.73 -0.68 0.50 6.86 -1.60 2.93 -3.67
Net Cash From Operating Activities
-0.77 2.95 1.26 -2.47 0.39 0.87 7.10 -1.55 2.84 -1.70
Net Cash From Continuing Operating Activities
-0.77 2.95 1.26 -2.47 0.32 0.87 7.10 -1.55 2.84 -1.70
Net Income / (Loss) Continuing Operations
-0.60 0.63 -3.04 -0.81 -2.26 -0.58 4.56 -2.66 0.91 -3.05
Consolidated Net Income / (Loss)
-0.60 0.63 -3.04 -0.81 -2.26 -0.58 4.56 -2.66 0.91 -3.05
Depreciation Expense
0.36 0.28 0.26 0.25 0.33 0.19 0.17 0.21 0.25 0.17
Amortization Expense
1.04 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income
-0.38 5.16 0.88 0.82 1.18 3.08 0.82 0.87 1.72 0.95
Changes in Operating Assets and Liabilities, net
-1.18 -3.13 3.14 -2.76 1.05 -1.85 1.52 -0.00 -0.07 0.19
Net Cash From Investing Activities
-38 - - -1.88 -0.78 - - 0.00 -0.01 -2.00
Net Cash From Continuing Investing Activities
-38 - - -1.88 -0.78 - - 0.00 -0.01 -2.00
Purchase of Property, Plant & Equipment
-0.01 - - -0.01 - - - 0.00 -0.01 -
Acquisitions
-38 - - -1.87 -0.78 - - 0.00 - -2.00
Net Cash From Financing Activities
34 -0.39 -0.22 -0.38 -0.29 -0.37 -0.25 -0.05 0.10 0.04
Net Cash From Continuing Financing Activities
34 -0.39 -0.22 -0.38 -0.29 -0.37 -0.25 -0.05 0.10 0.04
Other Financing Activities, net
1.02 - 0.17 0.01 -0.14 0.02 0.14 -0.05 -0.07 0.04
Cash Interest Paid
0.14 0.16 0.17 0.19 0.20 0.21 0.21 0.22 0.19 0.17
Cash Income Taxes Paid
-0.10 0.18 - 0.00 0.25 - - 0.00 - -

Annual Balance Sheets for Eton Pharmaceuticals

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
76 32 25
Total Current Assets
41 27 20
Cash & Equivalents
15 21 16
Accounts Receivable
5.36 3.41 1.85
Inventories, net
15 0.91 0.56
Prepaid Expenses
5.49 1.13 1.29
Plant, Property, & Equipment, net
0.03 0.06 0.07
Total Noncurrent Assets
35 4.84 4.95
Intangible Assets
35 4.74 4.75
Other Noncurrent Operating Assets
0.19 0.10 0.20
Total Liabilities & Shareholders' Equity
76 32 25
Total Liabilities
52 16 12
Total Current Liabilities
20 16 6.46
Short-Term Debt
0.00 5.38 1.03
Accounts Payable
4.17 1.85 1.77
Accrued Expenses
16 9.01 3.66
Total Noncurrent Liabilities
32 0.02 5.49
Long-Term Debt
30 0.00 5.38
Other Noncurrent Operating Liabilities
1.94 0.02 0.11
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
24 15 13
Total Preferred & Common Equity
24 15 13
Total Common Equity
24 15 13
Common Stock
132 120 116
Retained Earnings
-108 -104 -103

Quarterly Balance Sheets for Eton Pharmaceuticals

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
36 32 31 32 31 24 22
Total Current Assets
30 25 24 27 26 19 16
Cash & Equivalents
20 18 17 22 22 15 13
Accounts Receivable
5.59 4.87 4.24 3.50 3.08 2.87 1.50
Inventories, net
1.94 2.07 2.32 1.05 0.82 0.44 0.48
Prepaid Expenses
1.96 0.80 1.05 0.54 0.87 1.10 1.06
Plant, Property, & Equipment, net
0.03 0.05 0.06 0.04 0.05 0.06 0.07
Total Noncurrent Assets
6.06 6.34 6.47 4.33 4.55 4.75 5.03
Intangible Assets
5.85 6.12 6.39 4.21 4.39 4.57 4.97
Other Noncurrent Operating Assets
0.21 0.22 0.09 0.12 0.16 0.18 0.05
Total Liabilities & Shareholders' Equity
36 32 31 32 31 24 22
Total Liabilities
20 18 15 15 14 13 10
Total Current Liabilities
20 18 15 10 9.59 7.49 4.66
Short-Term Debt
4.13 4.66 5.02 1.54 1.54 1.34 0.71
Accounts Payable
2.68 2.13 2.26 1.71 2.30 1.23 1.05
Accrued Expenses
13 11 8.02 7.14 5.75 4.92 2.90
Total Noncurrent Liabilities
0.13 0.15 0.00 4.24 4.62 5.19 5.68
Other Noncurrent Operating Liabilities
0.13 0.15 0.00 0.04 0.07 0.09 -
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
16 13 15 17 17 11 11
Total Preferred & Common Equity
16 13 15 17 17 11 11
Total Common Equity
16 13 15 17 17 11 11
Common Stock
123 121 120 119 118 117 115
Retained Earnings
-107 -108 -105 -102 -101 -106 -104

Annual Metrics And Ratios for Eton Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
23.29% 48.90% -2.66%
EBITDA Growth
-572.04% 104.62% -316.37%
EBIT Growth
-452.69% 92.36% -288.84%
NOPAT Growth
-117.87% 85.57% -452.51%
Net Income Growth
-308.44% 89.62% -361.43%
EPS Growth
0.00% 0.00% 0.00%
Operating Cash Flow Growth
-85.78% 41.36% 202.12%
Free Cash Flow Firm Growth
-1,542.94% 209.72% 109.49%
Invested Capital Growth
7,501.69% -116.65% -67.79%
Revenue Q/Q Growth
12.50% -3.61% 12.76%
EBITDA Q/Q Growth
63.91% -89.37% -5.75%
EBIT Q/Q Growth
30.96% -132.12% -5.81%
NOPAT Q/Q Growth
50.24% -144.79% -3.15%
Net Income Q/Q Growth
30.25% -141.94% -1.43%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-54.31% -26.47% 253.73%
Free Cash Flow Firm Q/Q Growth
-1,317.07% -47.45% 109.14%
Invested Capital Q/Q Growth
25,456.77% -194.99% -23.85%
Profitability Metrics
- - -
Gross Margin
60.01% 66.56% 67.38%
EBITDA Margin
-3.98% 1.04% -33.50%
Operating Margin
-6.66% -3.77% -38.87%
EBIT Margin
-9.76% -2.18% -42.45%
Profit (Net Income) Margin
-9.80% -2.96% -42.45%
Tax Burden Percent
100.39% 135.85% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-9.38% -62.76% -88.32%
ROIC Less NNEP Spread (ROIC-NNEP)
344.57% -61.98% -51.54%
Return on Net Nonoperating Assets (RNNOA)
-9.78% 56.20% 29.56%
Return on Equity (ROE)
-19.16% -6.56% -58.75%
Cash Return on Invested Capital (CROIC)
-105.98% 0.00% 14.24%
Operating Return on Assets (OROA)
-7.06% -2.43% -34.37%
Return on Assets (ROA)
-7.09% -3.30% -34.37%
Return on Common Equity (ROCE)
-19.16% -6.56% -58.75%
Return on Equity Simple (ROE_SIMPLE)
-15.65% -6.05% -68.98%
Net Operating Profit after Tax (NOPAT)
-1.82 -0.83 -5.78
NOPAT Margin
-4.66% -2.64% -27.21%
Net Nonoperating Expense Percent (NNEP)
-353.95% -0.78% -36.78%
Return On Investment Capital (ROIC_SIMPLE)
-3.35% -4.00% -29.66%
Cost of Revenue to Revenue
39.99% 33.44% 32.62%
SG&A Expenses to Revenue
58.32% 59.83% 87.44%
R&D to Revenue
8.34% 10.50% 18.80%
Operating Expenses to Revenue
66.67% 70.33% 106.24%
Earnings before Interest and Taxes (EBIT)
-3.81 -0.69 -9.02
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-1.55 0.33 -7.12
Valuation Ratios
- - -
Price to Book Value (P/BV)
14.09 7.26 5.45
Price to Tangible Book Value (P/TBV)
0.00 10.47 8.57
Price to Revenue (P/Rev)
8.82 3.55 3.36
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
9.13 0.00 19.26
Enterprise Value to Revenue (EV/Rev)
9.20 3.05 2.89
Enterprise Value to EBITDA (EV/EBITDA)
0.00 292.94 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
370.50 14.14 12.75
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 33.39 65.93
Leverage & Solvency
- - -
Debt to Equity
1.22 0.35 0.49
Long-Term Debt to Equity
1.22 0.00 0.41
Financial Leverage
-0.03 -0.91 -0.57
Leverage Ratio
2.70 1.99 1.71
Compound Leverage Factor
2.70 1.99 1.71
Debt to Total Capital
54.96% 25.79% 32.92%
Short-Term Debt to Total Capital
0.00% 25.79% 5.30%
Long-Term Debt to Total Capital
54.96% 0.00% 27.62%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
45.04% 74.21% 67.08%
Debt to EBITDA
-19.20 16.35 -0.90
Net Debt to EBITDA
-9.58 -48.66 1.39
Long-Term Debt to EBITDA
-19.20 0.00 -0.76
Debt to NOPAT
-16.40 -6.45 -1.11
Net Debt to NOPAT
-8.18 19.19 1.71
Long-Term Debt to NOPAT
-16.40 0.00 -0.93
Altman Z-Score
2.69 0.88 -1.88
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.06 1.65 3.10
Quick Ratio
1.02 1.53 2.81
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-42 2.89 0.93
Operating Cash Flow to CapEx
3,726.92% 0.00% 12,686.84%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.72 1.11 0.81
Accounts Receivable Turnover
8.89 12.02 5.80
Inventory Turnover
1.93 14.42 12.53
Fixed Asset Turnover
848.07 486.80 227.28
Accounts Payable Turnover
5.19 5.86 3.92
Days Sales Outstanding (DSO)
41.04 30.36 62.89
Days Inventory Outstanding (DIO)
188.85 25.32 29.14
Days Payable Outstanding (DPO)
70.37 62.33 93.18
Cash Conversion Cycle (CCC)
159.52 -6.66 -1.16
Capital & Investment Metrics
- - -
Invested Capital
39 -0.53 3.19
Invested Capital Turnover
2.01 23.80 3.25
Increase / (Decrease) in Invested Capital
40 -3.72 -6.71
Enterprise Value (EV)
359 96 61
Market Capitalization
344 112 71
Book Value per Share
$0.95 $0.60 $0.52
Tangible Book Value per Share
($0.40) $0.42 $0.33
Total Capital
54 21 19
Total Debt
30 5.38 6.42
Total Long-Term Debt
30 0.00 5.38
Net Debt
15 -16 -9.89
Capital Expenditures (CapEx)
0.03 0.00 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
6.14 -5.41 -1.73
Debt-free Net Working Capital (DFNWC)
21 16 15
Net Working Capital (NWC)
21 11 14
Net Nonoperating Expense (NNE)
2.01 0.10 3.24
Net Nonoperating Obligations (NNO)
15 -16 -9.89
Total Depreciation and Amortization (D&A)
2.26 1.02 1.90
Debt-free, Cash-free Net Working Capital to Revenue
15.73% -17.10% -8.14%
Debt-free Net Working Capital to Revenue
54.02% 50.50% 68.59%
Net Working Capital to Revenue
54.02% 33.49% 63.73%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($0.15) ($0.04) ($0.36)
Adjusted Weighted Average Basic Shares Outstanding
25.90M 25.65M 25.15M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
26.82M 25.69M 25.46M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
26.82M 25.69M 25.46M
Normalized Net Operating Profit after Tax (NOPAT)
-1.82 -0.83 -5.78
Normalized NOPAT Margin
-4.66% -2.64% -27.21%
Pre Tax Income Margin
-9.76% -2.18% -42.45%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Eton Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
59.26% 46.90% -24.36% 50.19% -13.94% 118.33% 63.05% 143.75% 39.47% 315.35%
EBITDA Growth
141.90% 346.65% -154.25% 77.18% -334.34% 87.83% 3,615.83% 55.17% -31.88% 54.87%
EBIT Growth
74.59% 192.88% -162.67% 68.43% -520.96% 81.07% 449.48% 52.46% -47.64% 52.49%
NOPAT Growth
131.56% 266.06% -152.91% 68.43% -231.37% 81.07% 513.97% 50.19% -19.18% 50.49%
Net Income Growth
73.49% 208.29% -166.70% 69.51% -347.37% 80.99% 392.62% 50.09% -12.22% 50.03%
EPS Growth
0.00% 200.00% -166.67% 70.00% 0.00% 83.33% 400.00% 0.00% 0.00% 50.00%
Operating Cash Flow Growth
-297.67% 238.14% -82.33% -59.75% -86.37% 151.26% 188.62% -226.57% 155.50% 42.27%
Free Cash Flow Firm Growth
-1,793.70% -58.38% -123.70% -437.71% -70.09% 149.02% 387.78% 94.72% 204.25% -152.49%
Invested Capital Growth
7,501.69% -127.73% -65.97% 29.54% -116.65% -86.66% -50.94% -33.58% -67.79% 1,129.24%
Revenue Q/Q Growth
12.81% 13.78% 13.91% 8.93% 4.06% -41.42% 126.19% -37.59% 164.00% -56.25%
EBITDA Q/Q Growth
0.37% 130.52% -406.88% 73.69% -490.85% -106.71% 313.22% -377.15% 130.69% -1,838.85%
EBIT Q/Q Growth
-214.34% 117.34% -266.88% 65.07% -317.88% -111.70% 284.81% -565.81% 118.79% -116.04%
NOPAT Q/Q Growth
-30.88% 131.01% -266.88% 59.86% -263.69% -109.88% 318.91% -267.02% 152.41% -116.04%
Net Income Q/Q Growth
-195.37% 120.62% -274.97% 64.05% -289.64% -112.70% 271.39% -391.67% 129.95% -95.44%
EPS Q/Q Growth
0.00% 116.67% -300.00% 0.00% 0.00% -111.11% 280.00% 0.00% 0.00% -100.00%
Operating Cash Flow Q/Q Growth
-125.91% 135.22% 150.75% -739.02% -55.67% -87.71% 558.85% -154.51% 266.76% -169.20%
Free Cash Flow Firm Q/Q Growth
-3,015.87% 209.97% 14.69% -161.91% -28.35% -37.36% 2,035.40% -103.44% 217.42% -267.71%
Invested Capital Q/Q Growth
25,456.77% -136.39% -88.96% 826.74% -194.99% -55.35% -57.97% -6.61% -23.85% 64.15%
Profitability Metrics
- - - - - - - - - -
Gross Margin
55.60% 61.04% 62.00% 62.85% 49.64% 62.65% 80.70% 63.08% 74.84% 62.69%
EBITDA Margin
6.97% 7.84% -29.22% -6.57% -26.50% -4.67% 40.74% -43.21% 9.73% -83.72%
Operating Margin
5.40% 4.93% -32.35% -10.04% -27.25% -7.80% 32.37% -47.78% 12.50% -89.93%
EBIT Margin
-5.00% 4.93% -32.35% -10.04% -31.31% -7.80% 39.03% -47.78% 6.40% -89.93%
Profit (Net Income) Margin
-5.13% 6.07% -33.51% -10.18% -30.85% -8.24% 38.00% -50.15% 10.73% -94.59%
Tax Burden Percent
117.03% 125.15% 101.81% 100.00% 112.29% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
87.80% 98.43% 101.77% 101.38% 87.73% 105.66% 97.35% 104.97% 167.65% 105.18%
Effective Tax Rate
0.00% -25.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
7.61% 1,059.23% -846.86% -70.53% -454.03% -75.47% 493.80% -218.46% 40.56% -627.41%
ROIC Less NNEP Spread (ROIC-NNEP)
190.89% 1,059.29% -839.94% -68.01% -447.38% -73.80% 488.63% -208.13% 42.27% -618.58%
Return on Net Nonoperating Assets (RNNOA)
-5.42% -1,046.27% 793.25% 50.62% 405.72% 61.32% -426.61% 145.04% -24.24% 531.42%
Return on Equity (ROE)
2.19% 12.96% -53.61% -19.92% -48.31% -14.16% 67.19% -73.42% 16.32% -95.99%
Cash Return on Invested Capital (CROIC)
-105.98% 0.00% -425.17% -13.26% 0.00% 231.38% 50.54% -66.69% 14.24% -243.53%
Operating Return on Assets (OROA)
-3.61% 5.08% -32.35% -12.59% -34.91% -9.65% 41.97% -49.43% 5.18% -70.44%
Return on Assets (ROA)
-3.71% 6.25% -33.52% -12.76% -34.39% -10.20% 40.86% -51.89% 8.69% -74.09%
Return on Common Equity (ROCE)
2.19% 12.96% -53.61% -19.92% -48.31% -14.16% 67.19% -73.42% 16.32% -95.99%
Return on Equity Simple (ROE_SIMPLE)
0.00% -34.30% -49.67% 5.89% 0.00% 13.21% -1.40% -56.50% 0.00% -79.55%
Net Operating Profit after Tax (NOPAT)
0.44 0.64 -2.05 -0.56 -1.40 -0.38 3.88 -1.77 1.06 -2.03
NOPAT Margin
3.78% 6.17% -22.64% -7.03% -19.08% -5.46% 32.37% -33.44% 12.50% -62.95%
Net Nonoperating Expense Percent (NNEP)
-183.28% -0.06% -6.92% -2.52% -6.65% -1.68% 5.17% -10.33% -1.70% -8.83%
Return On Investment Capital (ROIC_SIMPLE)
0.81% - - - -6.69% - - - 5.45% -
Cost of Revenue to Revenue
44.40% 38.96% 38.00% 37.15% 50.36% 37.35% 19.30% 36.92% 25.16% 37.31%
SG&A Expenses to Revenue
57.68% 51.22% 61.62% 64.73% 62.57% 61.70% 38.96% 100.77% 51.24% 129.51%
R&D to Revenue
-7.48% 4.89% 32.73% 8.17% 14.32% 8.75% 9.38% 10.09% 11.11% 23.11%
Operating Expenses to Revenue
50.20% 56.11% 94.35% 72.90% 76.89% 70.45% 48.34% 110.86% 62.34% 152.63%
Earnings before Interest and Taxes (EBIT)
-0.58 0.51 -2.94 -0.80 -2.29 -0.55 4.68 -2.53 0.54 -2.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.81 0.81 -2.65 -0.52 -1.94 -0.33 4.89 -2.29 0.83 -2.70
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
14.09 9.70 6.28 6.22 7.26 6.33 5.32 8.72 5.45 4.75
Price to Tangible Book Value (P/TBV)
0.00 15.31 11.52 10.58 10.47 8.44 7.22 14.70 8.57 8.56
Price to Revenue (P/Rev)
8.82 4.47 2.69 2.81 3.55 3.26 3.07 4.02 3.36 2.82
Price to Earnings (P/E)
0.00 0.00 0.00 105.51 0.00 47.93 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.95% 0.00% 2.09% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
9.13 0.00 167.81 21.95 0.00 162.15 58.74 30.13 19.26 11.01
Enterprise Value to Revenue (EV/Rev)
9.20 4.01 2.28 2.47 3.05 2.76 2.53 3.68 2.89 2.45
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 40.37 292.94 29.30 101.15 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 81.05 0.00 42.26 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 198.54 0.00 48.65 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
370.50 65.48 1,702.05 14.38 14.14 9.78 10.99 43.78 12.75 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 33.39 16.50 76.51 0.00 65.93 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
1.22 0.26 0.35 0.32 0.35 0.34 0.36 0.57 0.49 0.57
Long-Term Debt to Equity
1.22 0.00 0.00 0.00 0.00 0.25 0.27 0.45 0.41 0.51
Financial Leverage
-0.03 -0.99 -0.94 -0.74 -0.91 -0.83 -0.87 -0.70 -0.57 -0.86
Leverage Ratio
2.70 2.05 2.08 2.05 1.99 1.89 1.80 1.91 1.71 1.79
Compound Leverage Factor
2.37 2.02 2.12 2.08 1.74 2.00 1.75 2.01 2.87 1.89
Debt to Total Capital
54.96% 20.52% 25.71% 24.47% 25.79% 25.35% 26.70% 36.44% 32.92% 36.35%
Short-Term Debt to Total Capital
0.00% 20.52% 25.71% 24.47% 25.79% 6.81% 6.75% 7.57% 5.30% 4.03%
Long-Term Debt to Total Capital
54.96% 0.00% 0.00% 0.00% 0.00% 18.55% 19.95% 28.87% 27.62% 32.32%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
45.04% 79.48% 74.29% 75.53% 74.21% 74.65% 73.30% 63.56% 67.08% 63.65%
Debt to EBITDA
-19.20 -0.96 -0.86 2.39 16.35 1.85 8.38 -1.50 -0.90 -0.95
Net Debt to EBITDA
-9.58 3.75 2.40 -5.55 -48.66 -5.28 -21.28 1.92 1.39 1.04
Long-Term Debt to EBITDA
-19.20 0.00 0.00 0.00 0.00 1.36 6.26 -1.19 -0.76 -0.84
Debt to NOPAT
-16.40 -1.13 -1.06 11.77 -6.45 3.08 -17.98 -1.61 -1.11 -1.14
Net Debt to NOPAT
-8.18 4.42 2.97 -27.27 19.19 -8.77 45.67 2.07 1.71 1.25
Long-Term Debt to NOPAT
-16.40 0.00 0.00 0.00 0.00 2.25 -13.44 -1.28 -0.93 -1.01
Altman Z-Score
2.83 1.84 -1.03 0.39 0.72 1.49 1.26 -0.30 -0.62 -2.60
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.06 1.51 1.40 1.59 1.65 2.61 2.75 2.55 3.10 3.52
Quick Ratio
1.02 1.31 1.24 1.37 1.53 2.46 2.57 2.35 2.81 3.19
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-39 1.35 -1.23 -1.44 2.33 3.25 5.18 -0.27 7.78 -6.62
Operating Cash Flow to CapEx
-6,375.00% 0.00% 0.00% -17,664.29% 0.00% 0.00% 0.00% 0.00% 23,666.67% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -44.15
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.35
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.35
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.72 1.03 1.00 1.25 1.11 1.24 1.08 1.03 0.81 0.78
Accounts Receivable Turnover
8.89 7.63 7.89 9.64 12.02 13.15 14.81 13.29 5.80 20.02
Inventory Turnover
1.93 9.44 8.82 8.41 14.42 11.80 11.30 16.98 12.53 12.77
Fixed Asset Turnover
848.07 976.82 689.69 607.15 486.80 591.48 436.36 295.50 227.28 182.09
Accounts Payable Turnover
5.19 6.42 5.74 6.63 5.86 6.53 4.23 4.78 3.92 2.41
Days Sales Outstanding (DSO)
41.04 47.82 46.27 37.85 30.36 27.76 24.64 27.47 62.89 18.23
Days Inventory Outstanding (DIO)
188.85 38.65 41.39 43.41 25.32 30.94 32.29 21.49 29.14 28.58
Days Payable Outstanding (DPO)
70.37 56.85 63.63 55.09 62.33 55.86 86.29 76.34 93.18 151.74
Cash Conversion Cycle (CCC)
159.52 29.62 24.04 26.17 -6.66 2.84 -29.35 -27.38 -1.16 -104.93
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
39 -0.16 0.43 3.86 -0.53 0.56 1.25 2.98 3.19 4.19
Invested Capital Turnover
2.01 171.67 37.40 10.03 23.80 13.83 15.26 6.53 3.25 9.97
Increase / (Decrease) in Invested Capital
40 -0.71 -0.83 0.88 -3.72 -3.63 -1.30 -1.51 -6.71 4.60
Enterprise Value (EV)
359 139 71 85 96 91 74 90 61 46
Market Capitalization
344 155 85 96 112 107 89 98 71 53
Book Value per Share
$0.95 $0.62 $0.52 $0.60 $0.60 $0.66 $0.66 $0.44 $0.52 $0.44
Tangible Book Value per Share
($0.40) $0.39 $0.29 $0.35 $0.42 $0.49 $0.48 $0.26 $0.33 $0.25
Total Capital
54 20 18 21 21 23 23 18 19 18
Total Debt
30 4.13 4.66 5.02 5.38 5.74 6.09 6.45 6.42 6.39
Total Long-Term Debt
30 0.00 0.00 0.00 0.00 4.20 4.55 5.11 5.38 5.68
Net Debt
15 -16 -13 -12 -16 -16 -15 -8.26 -9.89 -6.99
Capital Expenditures (CapEx)
0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
6.14 -6.12 -5.82 -2.67 -5.41 -3.77 -3.28 -1.75 -1.73 -0.91
Debt-free Net Working Capital (DFNWC)
21 14 12 14 16 18 18 13 15 12
Net Working Capital (NWC)
21 10 7.22 8.96 11 17 17 12 14 12
Net Nonoperating Expense (NNE)
1.04 0.01 0.99 0.25 0.86 0.20 -0.68 0.89 0.15 1.02
Net Nonoperating Obligations (NNO)
15 -16 -13 -12 -16 -16 -15 -8.26 -9.89 -6.99
Total Depreciation and Amortization (D&A)
1.39 0.30 0.28 0.28 0.35 0.22 0.20 0.24 0.28 0.20
Debt-free, Cash-free Net Working Capital to Revenue
15.73% -17.65% -18.54% -7.79% -17.10% -11.47% -11.31% -7.16% -8.14% -4.83%
Debt-free Net Working Capital to Revenue
54.02% 40.78% 37.84% 40.76% 50.50% 55.76% 63.01% 53.17% 68.59% 66.15%
Net Working Capital to Revenue
54.02% 28.88% 23.00% 26.13% 33.49% 51.07% 57.71% 47.68% 63.73% 62.40%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.02) $0.02 ($0.12) ($0.03) ($0.10) ($0.02) $0.18 ($100.00) $209.82 ($0.12)
Adjusted Weighted Average Basic Shares Outstanding
25.90M 25.90K 25.78M 25.76M 25.65M 25.72M 25.59M 25.53M 25.15M 25.37M
Adjusted Diluted Earnings per Share
$0.00 $0.02 ($0.12) ($0.03) $0.00 ($0.02) $0.18 $0.00 $0.00 ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding
26.82M 26.55K 25.78M 25.76M 25.69M 25.72M 25.98M 25.50M 25.46M 25.37M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
26.82M 25.84M 25.84M 25.69M 25.69M 25.66M 25.65M 25.50M 25.46M 25.30M
Normalized Net Operating Profit after Tax (NOPAT)
0.44 0.36 -2.05 -0.56 -1.40 -0.38 2.72 -1.77 0.74 -2.03
Normalized NOPAT Margin
3.78% 3.45% -22.64% -7.03% -19.08% -5.46% 22.66% -33.44% 8.75% -62.95%
Pre Tax Income Margin
-4.39% 4.85% -32.92% -10.18% -27.47% -8.24% 38.00% -50.15% 10.73% -94.59%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.30
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.51
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.30
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.51
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Eton Pharmaceuticals' Financials

When does Eton Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Eton Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Eton Pharmaceuticals' net income changed over the last 2 years?

Eton Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$3.82 million in 2024, falling from -$9.02 million in 2022. The previous period was -$936 thousand in 2023. See where experts think Eton Pharmaceuticals is headed by visiting Eton Pharmaceuticals' forecast page.

What is Eton Pharmaceuticals's operating income?
Eton Pharmaceuticals's total operating income in 2024 was -$2.60 million, based on the following breakdown:
  • Total Gross Profit: $23.41 million
  • Total Operating Expenses: $26.01 million
How has Eton Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Eton Pharmaceuticals' total revenue changed from $21.25 million in 2022 to $39.01 million in 2024, a change of 83.6%.

How much debt does Eton Pharmaceuticals have?

Eton Pharmaceuticals' total liabilities were at $51.70 million at the end of 2024, a 217.9% increase from 2023, and a 332.5% increase since 2022.

How much cash does Eton Pharmaceuticals have?

In the past 2 years, Eton Pharmaceuticals' cash and equivalents has ranged from $14.94 million in 2024 to $21.39 million in 2023, and is currently $14.94 million as of their latest financial filing in 2024.

How has Eton Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Eton Pharmaceuticals' book value per share changed from 0.52 in 2022 to 0.95 in 2024, a change of 82.9%.



This page (NASDAQ:ETON) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners